United States Plasma-Derived Therapeutics Market to hit US$ 35.10 Billion by 2033 | Top Companies 2025 - Takeda Pharmaceutical Company Limited, Johnson and Johnson

"The global plasma-derived therapeutics market was valued at US$ 20.16 Billion in 2023. The market size reached US$ 21.26 Billion in 2024 and is expected to reach US$ 35.10 Billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/plasma-derived-therapeutics-market?sp

United States: Recent Industry Developments

✅ In August 2025, Grifols launched a next-generation plasma-derived immunoglobulin therapy targeting primary immunodeficiency disorders. The therapy offers enhanced efficacy, improved patient tolerability, and streamlined administration protocols for chronic use.

✅ In July 2025, CSL Behring introduced an advanced albumin and clotting factor product designed to support patients with hemophilia and other rare blood disorders. The product integrates enhanced purification technology to ensure safety and consistency.

✅ In June 2025, Takeda Pharmaceuticals expanded its plasma-derived therapeutics portfolio with a novel hyperimmune globulin treatment aimed at emerging infectious diseases. The therapy provides targeted antibody support for high-risk populations.

Japan: Recent Industry Developments

✅ In August 2025, Japan Blood Products Organization launched a new plasma-derived immunoglobulin therapy to enhance treatment options for immune deficiency patients. The formulation focuses on safety, efficacy, and consistent therapeutic outcomes.

✅ In July 2025, Mitsubishi Tanabe Pharma introduced a recombinant clotting factor product for hemophilia patients, improving dosing flexibility and reducing immunogenic risk. The therapy supports better long-term disease management.

✅ In June 2025, Takeda Japan expanded its plasma-derived product offerings with hyperimmune globulin therapies targeting infectious and autoimmune conditions. The initiative aims to provide innovative treatment options for unmet clinical needs.

Plasma-Derived Therapeutics Market: Drivers

The plasma-derived therapeutics market is experiencing significant growth, driven by several key factors. Aging populations worldwide are leading to an increased prevalence of chronic and rare diseases, such as hemophilia, primary immunodeficiencies, and autoimmune disorders, thereby escalating the demand for plasma-derived therapies. Advancements in diagnostic technologies have improved the identification and treatment of these conditions, further boosting the need for specialized treatments. Additionally, there is a growing recognition of the clinical benefits of plasma-derived medicines, which has heightened awareness among healthcare providers and patients, leading to broader adoption. Government initiatives and regulatory support in various regions have also facilitated the development and accessibility of these therapies, contributing to market expansion. Furthermore, increased blood and plasma donations, supported by awareness campaigns, have enhanced the supply chain, ensuring a steady production of these life-saving treatments.

Technological advancements are playing a pivotal role in shaping the plasma-derived therapeutics market. Innovations in plasma fractionation and purification processes have improved the efficiency and safety of producing therapeutic proteins, enabling the development of more targeted and effective treatments. The application of artificial intelligence and bioanalytics is enhancing the understanding of the plasma proteome, leading to the discovery of new therapeutic targets and the development of next-generation therapies. Automation and robotics in manufacturing are streamlining production processes, reducing costs, and increasing scalability to meet the rising global demand. Additionally, advancements in recombinant technology are allowing for the production of therapies that mimic the properties of natural plasma proteins, expanding treatment options for patients. These technological strides are not only improving the quality and availability of plasma-derived therapeutics but are also paving the way for personalized medicine approaches, offering tailored treatments to individual patients.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/plasma-derived-therapeutics-market?sp

Plasma-Derived Therapeutics Market: Major Players

Takeda Pharmaceutical Company Limited, Johnson and Johnson (DePuy Synthes), Octapharma AG, Arthrex, Inc., Grifols, S.A., ADMA Biologics, Inc., CSL, Evolve Biologics Inc., Kamada Pharmaceuticals, and Bio Products Laboratory Ltd, among others.

Segment Covered in the Plasma-Derived Therapeutics Market:

➥ By Product Type: Protein, Coagulation Factors, Others

➥ By Application: Hemophilia, Idiopathic Thrombocytopenic Purpura (ITP), Primary Immunodeficiencies, Others

➥ By End-User: Hospitals & Specialty Clinics, Ambulatory Surgical Centers, Homecare Services, Others

Research Process:

Both primary and secondary data sources have been used in the Plasma-Derived Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Plasma-Derived Therapeutics Market Research Industry:

➠ Who leads the Plasma-Derived Therapeutics industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Plasma-Derived Therapeutics market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Plasma-Derived Therapeutics market growth?
➠ What are the dominant sales and distribution strategies in the Plasma-Derived Therapeutics industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=plasma-derived-therapeutics-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.